Devices and methods for enrichment and alteration of circulating tumor cells and other particles

• US 20070026417A1
• Filed: 12/29/2005
• Published: 02/01/2007
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Mehmet Toner
• Inventors: Toner, Mehmet, Fuchs, Martin
• Application Number:
  US11/323,962
• Publication Number:
  US 20070026417A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 2800/364 Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Claims

1. A method of detecting cancer cells in a cellular sample, said method comprising the steps of:

a) introducing said cellular sample into a device comprising a channel comprising a structure that directs said cancer cells in a first direction to produce a first output sample enriched in said cancer cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells; and

b) detecting the presence or absence of said cancer cells in said first output sample.

2. The method of claim 1, wherein said structure comprises an array of obstacles that form a network of gaps.

3. The method of claim 2, wherein said obstacles are capable of selectively capturing said cancer cells.

4. The method of claim 1, wherein said cellular sample is a blood sample.

5. The method of claim 1, wherein step b) comprises reacting said first output sample with an antibody to a marker for said cancer cells.

6. The method of claim 5, wherein said marker is selected from Table 1.

7. The method of claim 1, wherein step b) comprises determining the number of cells in said first output sample.

8. The method of claim 7, wherein said determining comprises determining the total amount of DNA in said first output sample.

9. The method of claim 1, wherein step b) comprises determining the number of said cancer cells in said first output sample.

10. The method of claim 9, said method further comprising determining the number of endothelial cells in said cellular sample.

11. The method of claim 10, further comprising determining the ratio of said cancer cells to said endothelial cells.

12. The method of claim 1, wherein step b) comprises detecting a mutation in DNA or RNA in said first output sample.

13. The method of claim 12, wherein said mutation is in a gene encoding a polypeptide listed in Table 1.

14. The method of claim 1, wherein step b) comprises analyzing protein phosphorylation, protein glycosylation, DNA methylation, microRNA levels, or cell morphology in said first output sample.

15. The method of claim 1, wherein step b) comprises detecting mitochondrial DNA, telomerase, or a nuclear matrix protein in said first output sample.

16. The method of claim 1, wherein step b) comprises detecting one or more mitochondrial abnormalities in said first output sample.

17. The method of claim 1, wherein step b) comprises detecting the presence or absence of perinuclear compartments in a cell of said first output sample.

18. The method of claim 1, wherein step b) comprises performing gene expression analysis, in-cell PCR, or fluorescence in-situ hybridization of said first output sample.

19. The method of claim 18, wherein said gene expression analysis is used to determine the tissue or tissues of origin of said cancer cells.

20. The method of claim 18, wherein said gene expression analysis is performed on a single cancer cell.

21. The method of claim 1, wherein said cellular sample comprises one or more progenitor endothelial cells, and wherein at least one of said progenitor endothelial cells is in said first output sample.

22. The method of claim 1, said device comprising a continuous flow device comprising a first inlet, a first outlet, and a second outlet, wherein said cellular sample is applied to said first inlet,said first output sample flows out of said first outlet, and said second output sample flows out of said second outlet.

23. The method of claim 22, wherein said second cells comprise non-cancer cells.

24. The method of claim 22, wherein said device comprises a second inlet, and wherein a second fluid is applied to said second inlet.

25. The method of claim 24, wherein said second fluid comprises a buffer, a lysis reagent, a nucleic acid amplification reagent, an osmolarity regulating reagent, a labeling reagent, a preservative, or a fixing reagent.

34. The method of claim 1, wherein said detecting comprises hyperspectral imaging of said first output sample.

35. The method of claim 1, wherein, prior to or concurrently with step a), said cellular sample is contacted with a labeling reagent that preferentially labels said cancer cells.

36. The method of claim 35, said labeling reagent comprising beads, wherein the hydrodynamic size of a labeled cancer cell is at least 10% greater than the hydrodynamic size of said cancer cell in the absence of said label.

43. The method of claim 1, wherein said channel comprises an array of obstacles forming a network of gaps, and wherein fluid flows through said gaps such that said fluid is divided unequally into a major flux and a minor flux.

26. A method of detecting cancer cells in a cellular sample, said method comprising the steps of:

a) enriching one or more of said cancer cells from said cellular sample without using magnetic particles, wherein said enriching is based on cell size, shape, or deformability; and

b) determining the number of said enriched cancer cells.

28. The method of claim 26 or 27, said method further comprising the steps of:

i) enriching one or more endothelial cells from said cellular sample; and

ii) determining the number of said enriched endothelial cells.

29. The method of claim 28, said method further comprising determining the ratio of said cancer cells to said endothelial cells.

30. The method of claim 26 or 27, wherein step b) comprises counting said enriched cancer cells.

31. The method of claim 26 or 27, wherein step b) comprises determining the total amount of DNA in said enriched cancer cells.

32. The method of claim 26 or 27, further comprising repeating steps a) and b) with a second cellular sample.

33. The method of claim 32, wherein said cellular sample and said second cellular sample are taken from a single subject.

27. A method of detecting cancer cells in a cellular sample, said method comprising the steps of:

a) enriching one or more of said cancer cells from said cellular sample without using an antibody or fragment thereof, wherein said enriching is based on cell size, shape, or deformability; and

b) determining the number of said enriching cancer cells.

37. A method for diagnosing a condition in a subject, said method comprising the steps of:

a) introducing a cellular sample from said subject into a device comprising a channel comprising a structure that directs one or more cancer cells in a first direction to produce a first output sample enriched in said cancer cells and one or more second cells in a second direction to produce a second output sample enriched in said second cells;

b) detecting the presence or absence of said cancer cells in said first output sample; and

c) diagnosing the presence or absence of said condition based on the results of step b).

38. The method of claim 37, further comprising imaging a portion of said subject prior to said diagnosis, wherein said diagnosis is further based on the results of said imaging.

39. The method of claim 38, wherein said imaging comprises computed axial tomography, positron emission tomography, or magnetic resonance imaging.

40. The method of claim 37, said method further comprising:

i) determining the number of endothelial cells in said cellular sample; and

ii) determining the ratio of said cancer cells to said endothelial cells,

wherein said diagnosis is further based on said ratio.

41. The method of claim 40, wherein said endothelial cells comprise progenitor endothelial cells.

42. The method of claim 40, wherein said condition is a hematological condition, an inflammatory condition, an ischemic condition, a neoplastic condition, infection, trauma, endometriosis, or kidney failure.